Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4588059 | 0.83 | ESR2 (0.45) | ESR1ESR2MTNR1AMTNR1BPOLA1 | |
| SCHEMBL4588054 | 0.83 | ESR2 (0.45) | ESR1ESR2MTNR1AMTNR1BPOLA1 | |
| SCHEMBL4590088 | 0.74 | SMN1; SMN2 (0.42) | ESR1CA2SMN1; SMN2MAPTLMNA | |
| SCHEMBL4588161 | 0.73 | HSD11B1 (0.41) | ESR1ESR2 | |
| SCHEMBL4588110 | 0.72 | ESR2 (0.67) | ESR1ESR2LMNAHSD17B1CYP2C9 | |
| SCHEMBL4589116 | 0.70 | MAPK1 (0.41) | ESR1ESR2MAPTLMNAHSD17B1 | |
| SCHEMBL6228939 | 0.70 | ESR2 (0.59) | ESR1ESR2HSD17B1 | |
| SCHEMBL4587924 | 0.70 | ESR2 (0.59) | ESR1ESR2HSD17B1 | |
| SCHEMBL4587928 | 0.70 | ESR2 (0.59) | ESR1ESR2HSD17B1 | |
| SCHEMBL6258442 | 0.66 | AKR1C3 (0.39) | ESR1SMN1; SMN2MAPTLMNAAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | ESRRA, ESR2, HSD17B11 | ESR1 7/4885ESR2 2/4885MTNR1A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.